ExpreS2ion to present new Nipah virus vaccine project in upcoming webcast
Hørsholm, Denmark, 12 December 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will provide a webcast update on the recently announced Nipah virus vaccine project on 14 December 2023.
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website.
14 December 2023 | Update on EU-Funded Nipah Virus Vaccine Project
10:00 CET | Virtual
ExpreS2ion Biotechnologies recently announced the award of a grant that amounts to EUR 8m (approx. SEK 90m) for the VICI-Disease consortium. 53% of the amount is a direct contribution to ExpreS2ion’s part of the project costs. The development project aims to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate.
CEO Bent Frandsen will dig deeper into the news in a live virtual event hosted by H.C. Andersen Capital on the Inderes platform. You can ask questions before or during the live event through the registration link here: https://www.inderes.dk/videos/expres2ion-biotechnologies-update-on-eu-funded-nipah-virus-vaccine-project
To pose questions ahead of time to be addressed at the webcast, please email ExpreS2ion at [email protected].
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
